Life Science Ind
ustry and BIOMED 2008
Israel is a world leader in the Life Science and the Healthcare industry.
Life Sciences Industry in Israel
consists of more than
companies working in the areas of
medical device, biotechnology,
cal and Ag
industry. It is a
young, growing and exuberant
75% of the Israeli
Life Sciences companies are less than a decade old and 40 % of companies were started in last 5 years.
industry is growing around 15% p.a. for last decade a
nd 50/60 new companies are incorporated every year.
Petah Tikva based Teva Pharmaceuticals is the oldest company, started in year 1901. Today
generic drug manufacturer in the world and one of the 20 largest pharmaceutical companies worldw
unique opportunities of major
diseases for which existing therapies are largely ineffective.
any Israeli companies are working on
treatments for cardiovascular and perip
heral vascular disease (73 companies), oncology (41),
neurodegenerative disease (32), and other age related diseases such as ophthalmic (16) and orthopedic
almost 50% of the total are working in
area of Medical Devices
. Biotech is the second largest sector with 156 companies or 21% and
Pharmaceutical is the third with 97 companies or 13% of all life science companies operated in Israel
Israel Life Science Industry
It is the largest sector of the Israeli Life Sciences Industry. It is divided into sub sectors
both implantable and disposable
diagnostic, imaging and monitoring
medical device companies focus the
ir product offering in over 20 applications. The
cardiology, gynecology, oncology, neurology and neurodegenerative disease,
ophthalmology and orthopedic.
A smaller number of companies focus on medical fields such as
endocrinology, wound ma
nagement and respiratory diseases.
sector is the second largest with 157 companies. The sector is fluid with new
companies being established and old one being abandoned.
Israel ranks fourth in the world in
after Japan, Germany and the UK
leader in medical device
is the third sector with
more than 100
companies. Although smaller in number
the largest and most established sector
in the Israeli Life sciences industry. It is the
largest revenue producer with 25 companies such as Teva, Agis, Taro and Dexcel Pharma, which are also
the largest employers in the Israeli industry. These companies are generally mature and focus their
ess on generic drugs.
A quarter of Israeli Pharma companies are
involved in the development of
The Israeli Life Science Industry
Number of Companies Founded
Israel’s Life S
“New Chemical Entity (NCE)”. Several others are involved in the development of drug delivery and
vaccines while others are focusing on the development of new dru
gs using natural compounds
strong presence in India and is collaborating with a number of companies. Last year, Taro was taken over
by Sun Pharmaceuticals from India.
Israel’s agriculture research is a major success story dating to
1909 when the wild ancestor of
Agriculture and scientific developments have produced
increasingly sophisticated and efficient agriculture systems
. For decades, Israel had an
dominated economy largely
based on citrus exports.
Today, Israeli Ag
Biotech companies are focused on
Replacing usage of toxic pesticides that endanger both man and the environment by biological control
Developing plants with desired characteristics based on molecular genetic te
Developing poultry and farm
Israel has world
class universities and research institutions such as the
Israel Institute of
Technology, the Weizmann Institute
of Sciences, and the Hebrew University of Jerusalem,
among leaders in the research on Life Science.
Strong collaborative relationship between
in moving cutting
research projects from the lab to commercialization
addition, there are
tech transfer orga
nizations (TTOs) within the
university system, five TTOs at
hospitals, and a
specialized TTO to advance the utilization of
military technology for medical applications.
nying the celebrations on occasion of the 60
anniversary of Israel’s
Life Science Conference
Biomed Israel 2008 and “The
International Stem Cell Meeting: The Potency of Stem Cells” conference to be
held from May 27
Over 5,000 scientists, engineers and managers attended the conference, with over 600
participants from abroad
attended the previous year’s conference.
to increase the exposure to t
he vast variety of Israeli BioPharma and Medical Device players. Close to 70
and numerous Poster presentations will be given during the
We cordially invite you to the BIOMED 2008 and
look forward to your suppor
. For further information contact the trade department of the Consulate General of Israel,
Mumbai or the Embassy of Israel in